Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 3/20 | 0.64 |
| ▸ | STS | P08842 | 7/20 | 0.55 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.53 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.45 |
| ▸ | ESR1 | P03372 | 5/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | PGR | P06401 | 2/20 | 0.41 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | AR | P10275 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SNCA | P37840 | 2/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29446097 | 0.96 | SHBG (0.70) | SHBGSTSAKR1C3HSD17B1ESR1 | |
| SCHEMBL975788 | 0.96 | SHBG (0.70) | SHBGSTSAKR1C3HSD17B1ESR1 | |
| SCHEMBL30887214 | 0.96 | SHBG (0.70) | SHBGSTSAKR1C3HSD17B1ESR1 | |
| SCHEMBL13725675 | 0.96 | SHBG (0.70) | SHBGSTSAKR1C3HSD17B1ESR1 | |
| SCHEMBL11096655 | 0.96 | SHBG (0.70) | SHBGSTSAKR1C3HSD17B1ESR1 | |
| Sulfamate SCHEMBL2451788 | 0.86 | STS (0.65) | SHBGSTSAKR1C3HSD17B1ESR1 | |
| SCHEMBL7703001 | 0.84 | SHBG (0.56) | SHBGSTSAKR1C3HSD17B1ESR1 | |
| SCHEMBL7043293 | 0.84 | STS (0.59) | SHBGSTSAKR1C3HSD17B1CYP2C9 | |
| SCHEMBL1257193 | 0.82 | SHBG (0.59) | SHBGSTSHSD17B1ESR1HSD17B10 | |
| Serine SCHEMBL11346267 | 0.80 | SHBG (0.54) | SHBGSTSAKR1C3HSD17B1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE42132-E1 | have special action with respect to tubulin polymerization inhibition and can be used for treating prostate cancer, breast cancer, colon cancer, non-small-cell-lung cancer, or primary dermal microvascular endothelial cell proliferation; 2-methoxy-17a-oxo-17a-homoestra-1,3,5(10)-trien-3-yl sulfamate | STERIX LIMITED (GB) | 2011-02-08 | — | — | US | disclosed |
| US-7244762-B2 | For therapy of prostate cancer | STERIX LIMITED (GB) | 2007-07-17 | — | — | US | disclosed |
| US-20060154985-A1 | Antitumoral d-homoestra-1,3,5 (10)-trien-3-yl 2-substituted sulfamates | STERIX LIMITED (GB) | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154985-A1 | Antitumoral d-homoestra-1,3,5 (10)-trien-3-yl 2-substituted sulfamates | TUBB1, TUBA1A, TUBB3 | SHBG 30/4885STS 27/4885AKR1C3 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.